Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

Authors not listed

CoMentis · 2007

Abstract

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2007). Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME). <em>CoMentis</em>. https://clinicaltrials.gov/study/NCT00536692
Vancouver
Anonymous. Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME). CoMentis. 2007.
BibTeX
@misc{anon2007PhaseS, title = {Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)}, author = {Anonymous}, journal = {CoMentis}, year = {2007}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings